Artelo Biosciences (NASDAQ:ARTL) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Artelo Biosciences (NASDAQ:ARTL) to a strong sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Artelo Biosciences currently has a consensus rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $3.77 on Friday. Artelo Biosciences has a one year low of $2.95 and a one year high of $85.80. The company has a market cap of $3.54 million, a price-to-earnings ratio of -0.06 and a beta of 0.41. The business’s 50 day moving average price is $5.11 and its 200 day moving average price is $5.73.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.